[1] |
FAN Jie, JIN Yongming, JIANG Xiaolong, JIANG Guohua.
Molecular mechanism of lncRNA HOTAIR regulating miR-206 on the proliferation and apoptosis of rheumatoid arthritis synovial cells
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 736-742.
|
[2] |
WANG Yan, ZHANG Jinhui, ZHAO Yongchen, LIU Hongxiang, LIU Yawei, MIAO Huanhuan, YANG Xincai.
Sequoiaflavone inhibits stem cell properties such as proliferation and invasion of gastric cancer cells by down-regulating PI3K/AKT signaling pathway
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 508-513.
|
[3] |
ZHOU Huan, XU Ming, LI Bo, LIU Chunying, WANG Chun.
PI3K/Akt/FOXO3a signaling pathway inducing protective autophagy promotes acquired lung adenocarcinoma resistance remodeling to DDP
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 961-970.
|
[4] |
DING Jiamin, WANG Youdi, ZHAO Xiali, JIANG Genfeng, CHEN Siwen, HONG Chengcheng, LI Shuqin, HU Weihua.
Study on the treatment of thin endometrium with growth hormone and vitamin E
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 857-862.
|
[5] |
SUI Yuxia, ZHUANG Jie, ZHUANG Min, HUANG Gui.
Delicaflavone inhibits the invasion and migration of gefitinib-resistant lung cancer PC-9/GR cells by regulating epithelial-mesenchymal transition via PI3K/Akt/mTOR pathway
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 614-621.
|
[6] |
WANG Xinli, XU Xiaqing, FANG Hanbing, GUO Yuzhong.
Study of TPA on enhancing the anti-tumor effects of cisplatin and reducing its renal toxicity
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 535-543.
|
[7] |
LI Yanyan, FANG Xiaojie, YIN Xin, SUN Xi, RAO Chunhui.
circZNF124 regulates the proliferation, migration and invasion of colorectal cancer SW620 cells by targeting miR-4262
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1231-1239.
|
[8] |
HE Jiaqi, LI Juanjuan, LV Xiaoai, ZHANG Huanhuan, YU Chenhuan.
Reversal effects and mechanisms of Flavonoids from Tetrastigma hemsleyanum on drug resistance in gefitinib-resistant lung cancer cells
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 368-375.
|
[9] |
CHEN Linjun, CHEN Wenbin.
Jolkinolide B inhibits the proliferation and metastasis of colon cancer cells via blocking PI3K/Akt/NF-κB pathway
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 250-257.
|
[10] |
PENG Fusheng, HUANG Xiaohui, LI Peng, TANG Jian'er.
miR-34a inhibits proliferation of prostate cancer LNCaP cells by regulating androgen receptor gene
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 10-17.
|
[11] |
WANG Xianghai, XING Min, LYU Tangfeng, LIU Hongbing, SONG Yong.
Effects of knocking down long intergenic non-coding RNA 00467 on the prognosis of patients with lung adenocarcinoma and its mechanism
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 841-849.
|
[12] |
HOU Bin, HUANG Weiping, YIN Zhongpu, HU Shousen.
lncRNA PCAT19 inhibits the proliferation and invasion of nasopharyngeal carcinoma cells by adsorbing miR-142-5p and regulating the expression of ING3 gene
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 721-727.
|
[13] |
HUANG Hao, XIAO Fang, JIA Hong, WANG Xiaoshuang, DUAN Yating.
miR-138-5p protects β cell function by regulating HIF-1α in gestational diabetes mellitus
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 489-497.
|
[14] |
OU Jun, HOU Wenwen, TANG Jingwen, LI Jiaping, XU Qingyang.
miR-106a regulates the proliferation of ovarian granulosa cells by targeting TIMP-2
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 527-532.
|
[15] |
HUANG Kang, LI Ling, YE Qifa, PENG Guizhu.
Expression of long non-coding RNA LINC00844 in hepatocellular carcinoma and its inhibiting effect on cell proliferation and migration
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 366-372.
|